Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Other Accumulated Expenses (2022 - 2025)

Historic Other Accumulated Expenses for Corvus Pharmaceuticals (CRVS) over the last 4 years, with Q3 2025 value amounting to $566000.0.

  • Corvus Pharmaceuticals' Other Accumulated Expenses rose 4079.6% to $566000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $566000.0, marking a year-over-year increase of 4079.6%. This contributed to the annual value of $289000.0 for FY2024, which is 1795.92% up from last year.
  • Latest data reveals that Corvus Pharmaceuticals reported Other Accumulated Expenses of $566000.0 as of Q3 2025, which was up 4079.6% from $346000.0 recorded in Q2 2025.
  • In the past 5 years, Corvus Pharmaceuticals' Other Accumulated Expenses ranged from a high of $566000.0 in Q3 2025 and a low of $131000.0 during Q2 2022
  • For the 4-year period, Corvus Pharmaceuticals' Other Accumulated Expenses averaged around $266666.7, with its median value being $245000.0 (2023).
  • Its Other Accumulated Expenses has fluctuated over the past 5 years, first skyrocketed by 8578.43% in 2023, then tumbled by 5277.04% in 2024.
  • Over the past 4 years, Corvus Pharmaceuticals' Other Accumulated Expenses (Quarter) stood at $158000.0 in 2022, then soared by 55.06% to $245000.0 in 2023, then rose by 17.96% to $289000.0 in 2024, then soared by 95.85% to $566000.0 in 2025.
  • Its Other Accumulated Expenses stands at $566000.0 for Q3 2025, versus $346000.0 for Q2 2025 and $296000.0 for Q1 2025.